ARAY · Accuray Inc
One customer — 17% of revenue (the three months ended March 31, 2026)
“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”
One customer — 16% of revenue (the nine months ended March 31, 2026)
“The JV represented approximately 17% and 21% of our total net revenue during the three months ended March 31, 2026 and 2025 respectively, and represented approximately 16% and 27% of our total net revenue during the nine months ended March 31, 2026 and 2025 respectively.”
One customer — 13% of receivables (As of March 31, 2026)
“As of March 31, 2026, and June 30, 2025, the JV represented approximately 13% and 33%, respectively, of our total accounts receivable balance.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross orders | 191.9M | year ended June 30, 2026 filing | — |
| Order backlog at the end of the period | 312.55M | year ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $10.6M | fiscal 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income (loss) -49.19M
+7.94M Depreciation and amortization
+6.46M Stock-based compensation
+32.09M Interest expense, net
+0K Gain on extinguishment of debt
+1.95M Provision for income taxes
-8.37M (Gain) loss from change in fair value of warrant liability
+2.41M IEEPA refund financing Costs
+16.17M Restructuring charges
+1.15M Post financing cost
= Adjusted EBITDA 10.6M
|
|||
| Book to bill ratio | 1.1 | Twelve Months Ended June 30, 2026 | — |
| Gross product orders | $191.9M | fiscal 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARAY
this stock
Accuray Inc
|
$33.56M | -63.2% | -12.3% | — | 4.1% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARAY | +0.6% | +11.7% | -24.6% | +11.7% | -63.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -0.6% | +11.1% | -36.2% | +10.1% | -76.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.